International – Moderna launches phase 1/2 study of mRNA-based flu vaccine

Moderna has announced the launch of a phase 1/2 study of its quadrivalent seasonal flu mRNA vaccine candidate, developed using the same platform used for its COVID-19 jab.

As a specialist in the mRNA field, Moderna has already found great success with its mRNA COVID-19 vaccine – mRNA-1273 – which was one of the first vaccines to be approved for the virus in the EU at the beginning of the year.

Now, Moderna is looking to extend that success into seasonal flu, while also progressing various studies for potential booster doses of its COVID-19 vaccine.

The flu vaccine candidate – known as mRNA-1010 – is Moderna’s first seasonal influenza vaccine to enter the clinic. It will target the lineages recommended by the World Health Organization (WHO) for the prevention of flu, including seasonal influenza A H1N1, H3N2 and influenza B Yamagata and Victoria…